Autolus Therapeutics
AUTL
51 hedge funds and large institutions have $96.4M invested in Autolus Therapeutics in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 21 increasing their positions, 10 reducing their positions, and 11 closing their positions.
110% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 10
0.74% more ownership
Funds ownership: 29.84% → 30.59% (+0.74%)
7% less funds holding
Funds holding: 55 → 51 (-4)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
46% less capital invested
Capital invested by funds: $177M → $96.4M (-$80.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$7.02M |
| 2 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
+$6.31M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$5.27M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$5.06M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$5.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.4M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$1.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.77M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.03M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$821K |
AUTL Hedge Fund Activity: Q1 2020 in Review
51 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q1 2020, worth a combined $96.4M — down 46% from $177M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of AUTL and 9 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 21 added.
The largest buyer was Capital World Investors, adding an estimated $7.02M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $12.4M sold.
- 51 institutional investors held Autolus Therapeutics (AUTL) as of Q1 2020, down from 55 in Q4 2019.
- Funds reported $96.4M of Autolus Therapeutics stock for Q1 2020, down 46% quarter-over-quarter.
- 9 funds opened new Autolus Therapeutics positions in Q1 2020 and 11 closed out, a net change of -2 holders.
- The largest Autolus Therapeutics buyer in Q1 2020 was Capital World Investors, an estimated $7.02M added.
- The largest Autolus Therapeutics seller in Q1 2020 was T. Rowe Price Associates, an estimated $12.4M sold.
Based on aggregated 13F filings for Q1 2020.